Shopping Cart 0
Cart Subtotal
USD 0

Infectious Disease Therapeutics Market on the basis of Mode of Treatment (Drugs and Vaccines), Disease Indication (Tuberculosis, HIV/AIDS, Influenza, Hepatitis, and Others), Distribution Channel (hospital pharmacy, retail pharmacy, and Others) and Geography - Global Forecast up to 2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 4000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 4500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 5500

Details

Infectious diseases proliferate among people directly or indirectly and are commonly caused by pathogenic microorganisms such as viruses, bacteria, fungi, and parasites. Anti-infective drugs are effective drugs that prevent the proliferation of such diseases. These drugs specifically target the causative agent, which is known as a mechanism of the host defense system. The key diseases causing numerous deaths globally are infectious diseases, including HIV, malaria, tuberculosis, influenza, hepatitis A, and hepatitis C. The Infectious Disease Therapeutics Market is anticipated to grow at the rate of 8.9% CAGR by 2027. A growing incidence of infectious diseases around the world has majorly created a demand for infectious disease therapeutics, which acts as driving factors in the infectious disease therapeutics market. Moreover, few other factors responsible for the major growth of the infectious disease therapeutics market in the forecast period are the favorable reimbursement policies for infectious diseases coupled with an increasing number of individuals affected with cancer which weakens the immunity system, therefore attracting several infectious diseases. But, a limited number of skilled persons in manufacturing effective drugs is a key factor negatively impacting the market growth.

Infectious Disease Therapeutics Market on the basis of Mode of Treatment

Drugs

Vaccines

Infectious Disease Therapeutics Market based on Disease Indication

Tuberculosis

HIV/AIDS

Influenza

Hepatitis

Others

Infectious Disease Therapeutics Market based on Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Others

Infectious Disease Therapeutics Market based on Geography

North America

Europe

Asia Pacific

Rest of the World

Based on the mode of treatment, the infectious disease therapeutics market is bifurcated into drugs and vaccines. The drug mode of treatment is projected to have a significant share in the market. This is because the increasing population of old around the world is a major attribute to augmenting segment growth. Furthermore, the growing expenditure on healthcare, particularly in the developed countries, is also surging the segment growth.

Based on the disease indication, the infectious disease therapeutics market is segmented by Tuberculosis, HIV/AIDS, Influenza, Hepatitis, and Others. The hepatitis segment is expected to register the highest growth rate in the coming years. The increasing incidence of hepatitis, growing clinical trial activities for the advent of new drugs, and a rising number of initiatives to elevate the adoption of drugs are projected to be the factors responsible for the segment's growth.

Further, the infectious disease therapeutics market is divided into hospital pharmacy, retail pharmacy, and others based on the distribution channel. The hospital pharmacy segment held the maximum share in the market. This is ascribed to the increase in hospital construction with the advanced equipment, and availability of professionals in the hospitals are the key factors.

In the geography market, the geographical regions are categorized into North America, Europe, Asia Pacific, and the rest of the world. Among all the regions, North America has acquired a leading share in the market. Increasing incidence of infectious diseases and favorable reimbursement scenarios are key factors expected to boost infectious disease therapeutics in the region.

The global market for infectious disease therapeutics is significantly driven by the surging number of infectious diseases worldwide, which has surged the demand for therapeutics for infectious diseases. The key reason for the rising number of infectious diseases is the increasing population worldwide, specifically in developing countries including Japan, India, and many other countries.

Top competitors operating in the global infectious disease therapeutics market are Gilead Sciences, Inc., BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Janssen Pharmaceutical, Novartis International AG and Astellas Pharma.

Henceforth, the vital burden on public health is presented by various infectious diseases such as HIV, malaria, tuberculosis, hepatitis A, hepatitis C, hepatitis C, and influenza. Therefore, most of the deaths are caused due to infectious diseases where new therapeutics such as drugs and vaccines are having a prominent role in preventing these diseases.

This study consists of information such as infectious disease therapeutics market dynamics scenarios and opportunities over the forecast period.

The report provides regional, sub-regional, and country-level analysis, including the demand and supply forces and their influence on the infectious disease therapeutics market.

The competitive landscape includes the share of key players, new developments, and strategies in the past few years.

This report also includes the comprehensive companies providing products, relevant financial information, recent developments, SWOT analysis, and strategies by these infectious disease therapeutics market players.

READ MORE

Table Of Content

Scope

Table of Contents

1. Executive Summary

2. Industry Outlook

2.1. Industry Overview

2.2. Industry Trends

3. Market Snapshot

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

4. Market characteristics

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO-Impact Analysis

5. Mode of Treatment: Market Size & Analysis

5.1. Overview

5.2. Drugs

5.3. Vaccines

6. Disease Indication: Market Size & Analysis

6.1. Overview

6.2. Tuberculosis

6.3. HIV/AIDS

6.4. Influenza

6.5. Hepatitis

6.6. Others

7. Distribution Channel: Market Size & Analysis

7.1. Overview

7.2. Hospital Pharmacy

7.3. Retail Pharmacy

7.4. Others

8. Geography: Market Size & Analysis

8.1. Overview

8.2. North America

8.3. Europe

8.4. Asia Pacific

8.5. Rest of the World

9. Competitive Landscape

9.1. Competitor Comparison Analysis

9.2. Market Developments

9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships

9.2.2. Product Launches and execution

10. Vendor Profiles

10.1. Gilead Sciences, Inc.

10.1.1. Overview

10.1.2. Financial Overview

10.1.3. Product Offerings

10.1.4. Developments

10.1.5. Business Strategy

10.2. BioCryst Pharmaceuticals, Inc.

10.2.1. Overview

10.2.2. Financial Overview

10.2.3. Product Offerings

10.2.4. Developments

10.2.5. Business Strategy

10.3. F. Hoffmann-La Roche AG

10.3.1. Overview

10.3.2. Financial Overview

10.3.3. Product Offerings

10.3.4. Developments

10.3.5. Business Strategy

10.4. Merck & Co., Inc.

10.4.1. Overview

10.4.2. Financial Overview

10.4.3. Product Offerings

10.4.4. Developments

10.4.5. Business Strategy

10.5. Johnson & Johnson

10.5.1. Overview

10.5.2. Financial Overview

10.5.3. Product Offerings

10.5.4. Developments

10.5.5. Business Strategy

10.6. Boehringer Ingelheim GmbH

10.6.1. Overview

10.6.2. Financial Overview

10.6.3. Product Offerings

10.6.4. Developments

10.6.5. Business Strategy

10.7. GlaxoSmithKline plc

10.7.1. Overview

10.7.2. Financial Overview

10.7.3. Product Offerings

10.7.4. Developments

10.7.5. Business Strategy

10.8. Janssen Pharmaceutical

10.8.1. Overview

10.8.2. Financial Overview

10.8.3. Product Offerings

10.8.4. Developments

10.8.5. Business Strategy

10.9. Novartis International AG

10.9.1. Overview

10.9.2. Financial Overview

10.9.3. Product Offerings

10.9.4. Developments

10.9.5. Business Strategy

10.10. Astellas Pharma

10.10.1. Overview

10.10.2. Financial Overview

10.10.3. Product Offerings

10.10.4. Developments

10.10.5. Business Strategy

11. Analyst Opinion

12. Annexure

12.1. Report Scope

12.2. Market Definitions

12.3. Research Methodology

12.3.1. Data Collation and In-house Estimation

12.3.2. Market Triangulation

12.3.3. Forecasting

12.4. Report Assumptions

12.5. Declarations

12.6. Stakeholders

12.7. Abbreviations


List Of Figure

Charts

CHART. 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR TUBERCULOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HIV/AIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 14. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 15. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 16. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 17. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 18. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 19. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 20. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 21. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 22. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 23. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 24. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 25. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 26. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 27. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 28. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 29. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 30. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 31. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 32. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 33. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 34. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 35. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 36. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 37. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 38. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 39. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 40. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 41. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 42. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 43. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 44. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 45. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 46. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 47. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 48. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 49. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 50. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 51. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 52. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 53. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 54. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 55. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 56. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 57. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 58. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 59. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 60. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 61. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 62. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 63. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 64. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)


List Of Table

Tables

TABLE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR TUBERCULOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HIV/AIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 15. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 16. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 17. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 18. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 19. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 20. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 21. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 22. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 23. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 24. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 25. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 26. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 27. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 28. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 29. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 30. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 31. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 32. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 33. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 34. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 35. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 36. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 37. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 38. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 39. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 40. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 41. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 42. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 43. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 44. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 45. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 47. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 48. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 49. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 50. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 51. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 52. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 53. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 54. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 55. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 56. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 57. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 58. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 59. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 60. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 61. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 62. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 63. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 64. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 65. GILEAD SCIENCES, INC: FINANCIALS

TABLE 66. GILEAD SCIENCES, INC: PRODUCTS & SERVICES

TABLE 67. GILEAD SCIENCES, INC: RECENT DEVELOPMENTS

TABLE 68. BIOCRYST PHARMACEUTICALS, INC: FINANCIALS

TABLE 69. BIOCRYST PHARMACEUTICALS, INC: PRODUCTS & SERVICES

TABLE 70. BIOCRYST PHARMACEUTICALS, INC: RECENT DEVELOPMENTS

TABLE 71. F. HOFFMANN-LA ROCHE AG: FINANCIALS

TABLE 72. F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES

TABLE 73. F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS

TABLE 74. MERCK & CO., INC: FINANCIALS

TABLE 75. MERCK & CO., INC: PRODUCTS & SERVICES

TABLE 76. MERCK & CO., INC: RECENT DEVELOPMENTS

TABLE 77. JOHNSON & JOHNSON: FINANCIALS

TABLE 78. JOHNSON & JOHNSON: PRODUCTS & SERVICES

TABLE 79. JOHNSON & JOHNSON: RECENT DEVELOPMENTS

TABLE 80. BOEHRINGER INGELHEIM GMBH: FINANCIALS

TABLE 81. BOEHRINGER INGELHEIM GMBH: PRODUCTS & SERVICES

TABLE 82. BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS

TABLE 83. GLAXOSMITHKLINE PLC: FINANCIALS

TABLE 84. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES

TABLE 85. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

TABLE 86. JANSSEN PHARMACEUTICAL: FINANCIALS

TABLE 87. JANSSEN PHARMACEUTICAL: PRODUCTS & SERVICES

TABLE 88. JANSSEN PHARMACEUTICAL: RECENT DEVELOPMENTS

TABLE 89. NOVARTIS INTERNATIONAL AG: FINANCIALS

TABLE 90. NOVARTIS INTERNATIONAL AG: PRODUCTS & SERVICES

TABLE 91. NOVARTIS INTERNATIONAL AG: RECENT DEVELOPMENTS

TABLE 92. ASTELLAS PHARMA: FINANCIALS

TABLE 93. ASTELLAS PHARMA: PRODUCTS & SERVICES

TABLE 94. ASTELLAS PHARMA: RECENT DEVELOPMENTS

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Gilead Sciences, Inc., BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Janssen Pharmaceutical, Novartis International AG and Astellas Pharma.

Company Profile

Company Profile Title

Infectious diseases proliferate among people directly or indirectly and are commonly caused by pathogenic microorganisms such as viruses, bacteria, fungi, and parasites. Anti-infective drugs are effective drugs that prevent the proliferation of such diseases. These drugs specifically target the causative agent, which is known as a mechanism of the host defense system. The key diseases causing numerous deaths globally are infectious diseases, including HIV, malaria, tuberculosis, influenza, hepatitis A, and hepatitis C. The Infectious Disease Therapeutics Market is anticipated to grow at the rate of 8.9% CAGR by 2027. A growing incidence of infectious diseases around the world has majorly created a demand for infectious disease therapeutics, which acts as driving factors in the infectious disease therapeutics market. Moreover, few other factors responsible for the major growth of the infectious disease therapeutics market in the forecast period are the favorable reimbursement policies for infectious diseases coupled with an increasing number of individuals affected with cancer which weakens the immunity system, therefore attracting several infectious diseases. But, a limited number of skilled persons in manufacturing effective drugs is a key factor negatively impacting the market growth.

Infectious Disease Therapeutics Market on the basis of Mode of Treatment

Drugs

Vaccines

Infectious Disease Therapeutics Market based on Disease Indication

Tuberculosis

HIV/AIDS

Influenza

Hepatitis

Others

Infectious Disease Therapeutics Market based on Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Others

Infectious Disease Therapeutics Market based on Geography

North America

Europe

Asia Pacific

Rest of the World

Based on the mode of treatment, the infectious disease therapeutics market is bifurcated into drugs and vaccines. The drug mode of treatment is projected to have a significant share in the market. This is because the increasing population of old around the world is a major attribute to augmenting segment growth. Furthermore, the growing expenditure on healthcare, particularly in the developed countries, is also surging the segment growth.

Based on the disease indication, the infectious disease therapeutics market is segmented by Tuberculosis, HIV/AIDS, Influenza, Hepatitis, and Others. The hepatitis segment is expected to register the highest growth rate in the coming years. The increasing incidence of hepatitis, growing clinical trial activities for the advent of new drugs, and a rising number of initiatives to elevate the adoption of drugs are projected to be the factors responsible for the segment's growth.

Further, the infectious disease therapeutics market is divided into hospital pharmacy, retail pharmacy, and others based on the distribution channel. The hospital pharmacy segment held the maximum share in the market. This is ascribed to the increase in hospital construction with the advanced equipment, and availability of professionals in the hospitals are the key factors.

In the geography market, the geographical regions are categorized into North America, Europe, Asia Pacific, and the rest of the world. Among all the regions, North America has acquired a leading share in the market. Increasing incidence of infectious diseases and favorable reimbursement scenarios are key factors expected to boost infectious disease therapeutics in the region.

The global market for infectious disease therapeutics is significantly driven by the surging number of infectious diseases worldwide, which has surged the demand for therapeutics for infectious diseases. The key reason for the rising number of infectious diseases is the increasing population worldwide, specifically in developing countries including Japan, India, and many other countries.

Top competitors operating in the global infectious disease therapeutics market are Gilead Sciences, Inc., BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Janssen Pharmaceutical, Novartis International AG and Astellas Pharma.

Henceforth, the vital burden on public health is presented by various infectious diseases such as HIV, malaria, tuberculosis, hepatitis A, hepatitis C, hepatitis C, and influenza. Therefore, most of the deaths are caused due to infectious diseases where new therapeutics such as drugs and vaccines are having a prominent role in preventing these diseases.

This study consists of information such as infectious disease therapeutics market dynamics scenarios and opportunities over the forecast period.

The report provides regional, sub-regional, and country-level analysis, including the demand and supply forces and their influence on the infectious disease therapeutics market.

The competitive landscape includes the share of key players, new developments, and strategies in the past few years.

This report also includes the comprehensive companies providing products, relevant financial information, recent developments, SWOT analysis, and strategies by these infectious disease therapeutics market players.

READ MORE

Scope

Table of Contents

1. Executive Summary

2. Industry Outlook

2.1. Industry Overview

2.2. Industry Trends

3. Market Snapshot

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

4. Market characteristics

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO-Impact Analysis

5. Mode of Treatment: Market Size & Analysis

5.1. Overview

5.2. Drugs

5.3. Vaccines

6. Disease Indication: Market Size & Analysis

6.1. Overview

6.2. Tuberculosis

6.3. HIV/AIDS

6.4. Influenza

6.5. Hepatitis

6.6. Others

7. Distribution Channel: Market Size & Analysis

7.1. Overview

7.2. Hospital Pharmacy

7.3. Retail Pharmacy

7.4. Others

8. Geography: Market Size & Analysis

8.1. Overview

8.2. North America

8.3. Europe

8.4. Asia Pacific

8.5. Rest of the World

9. Competitive Landscape

9.1. Competitor Comparison Analysis

9.2. Market Developments

9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships

9.2.2. Product Launches and execution

10. Vendor Profiles

10.1. Gilead Sciences, Inc.

10.1.1. Overview

10.1.2. Financial Overview

10.1.3. Product Offerings

10.1.4. Developments

10.1.5. Business Strategy

10.2. BioCryst Pharmaceuticals, Inc.

10.2.1. Overview

10.2.2. Financial Overview

10.2.3. Product Offerings

10.2.4. Developments

10.2.5. Business Strategy

10.3. F. Hoffmann-La Roche AG

10.3.1. Overview

10.3.2. Financial Overview

10.3.3. Product Offerings

10.3.4. Developments

10.3.5. Business Strategy

10.4. Merck & Co., Inc.

10.4.1. Overview

10.4.2. Financial Overview

10.4.3. Product Offerings

10.4.4. Developments

10.4.5. Business Strategy

10.5. Johnson & Johnson

10.5.1. Overview

10.5.2. Financial Overview

10.5.3. Product Offerings

10.5.4. Developments

10.5.5. Business Strategy

10.6. Boehringer Ingelheim GmbH

10.6.1. Overview

10.6.2. Financial Overview

10.6.3. Product Offerings

10.6.4. Developments

10.6.5. Business Strategy

10.7. GlaxoSmithKline plc

10.7.1. Overview

10.7.2. Financial Overview

10.7.3. Product Offerings

10.7.4. Developments

10.7.5. Business Strategy

10.8. Janssen Pharmaceutical

10.8.1. Overview

10.8.2. Financial Overview

10.8.3. Product Offerings

10.8.4. Developments

10.8.5. Business Strategy

10.9. Novartis International AG

10.9.1. Overview

10.9.2. Financial Overview

10.9.3. Product Offerings

10.9.4. Developments

10.9.5. Business Strategy

10.10. Astellas Pharma

10.10.1. Overview

10.10.2. Financial Overview

10.10.3. Product Offerings

10.10.4. Developments

10.10.5. Business Strategy

11. Analyst Opinion

12. Annexure

12.1. Report Scope

12.2. Market Definitions

12.3. Research Methodology

12.3.1. Data Collation and In-house Estimation

12.3.2. Market Triangulation

12.3.3. Forecasting

12.4. Report Assumptions

12.5. Declarations

12.6. Stakeholders

12.7. Abbreviations


List Of Figure

Charts

CHART. 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR TUBERCULOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HIV/AIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

CHART. 14. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 15. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 16. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 17. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 18. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 19. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 20. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 21. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 22. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 23. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 24. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 25. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 26. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 27. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 28. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 29. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 30. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 31. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 32. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 33. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 34. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 35. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 36. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 37. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 38. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 39. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 40. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 41. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 42. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 43. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 44. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 45. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 46. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

CHART. 47. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 48. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 49. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 50. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 51. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 52. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 53. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 54. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 55. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 56. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 57. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 58. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 59. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 60. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 61. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

CHART. 62. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

CHART. 63. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

CHART. 64. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)


List Of Table

Tables

TABLE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR TUBERCULOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HIV/AIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 15. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 16. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 17. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 18. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 19. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 20. U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 21. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 22. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 23. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 24. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 25. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 26. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 27. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 28. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 29. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 30. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 31. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 32. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 33. U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 34. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 35. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 36. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 37. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 38. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 39. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 40. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 41. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 42. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 43. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 44. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 45. ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 47. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 48. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 49. ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 50. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 51. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 52. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 53. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 54. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 55. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 56. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 57. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 58. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 59. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 60. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 61. REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 62. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 63. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 64. REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 65. GILEAD SCIENCES, INC: FINANCIALS

TABLE 66. GILEAD SCIENCES, INC: PRODUCTS & SERVICES

TABLE 67. GILEAD SCIENCES, INC: RECENT DEVELOPMENTS

TABLE 68. BIOCRYST PHARMACEUTICALS, INC: FINANCIALS

TABLE 69. BIOCRYST PHARMACEUTICALS, INC: PRODUCTS & SERVICES

TABLE 70. BIOCRYST PHARMACEUTICALS, INC: RECENT DEVELOPMENTS

TABLE 71. F. HOFFMANN-LA ROCHE AG: FINANCIALS

TABLE 72. F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES

TABLE 73. F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS

TABLE 74. MERCK & CO., INC: FINANCIALS

TABLE 75. MERCK & CO., INC: PRODUCTS & SERVICES

TABLE 76. MERCK & CO., INC: RECENT DEVELOPMENTS

TABLE 77. JOHNSON & JOHNSON: FINANCIALS

TABLE 78. JOHNSON & JOHNSON: PRODUCTS & SERVICES

TABLE 79. JOHNSON & JOHNSON: RECENT DEVELOPMENTS

TABLE 80. BOEHRINGER INGELHEIM GMBH: FINANCIALS

TABLE 81. BOEHRINGER INGELHEIM GMBH: PRODUCTS & SERVICES

TABLE 82. BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS

TABLE 83. GLAXOSMITHKLINE PLC: FINANCIALS

TABLE 84. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES

TABLE 85. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

TABLE 86. JANSSEN PHARMACEUTICAL: FINANCIALS

TABLE 87. JANSSEN PHARMACEUTICAL: PRODUCTS & SERVICES

TABLE 88. JANSSEN PHARMACEUTICAL: RECENT DEVELOPMENTS

TABLE 89. NOVARTIS INTERNATIONAL AG: FINANCIALS

TABLE 90. NOVARTIS INTERNATIONAL AG: PRODUCTS & SERVICES

TABLE 91. NOVARTIS INTERNATIONAL AG: RECENT DEVELOPMENTS

TABLE 92. ASTELLAS PHARMA: FINANCIALS

TABLE 93. ASTELLAS PHARMA: PRODUCTS & SERVICES

TABLE 94. ASTELLAS PHARMA: RECENT DEVELOPMENTS

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Gilead Sciences, Inc., BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Janssen Pharmaceutical, Novartis International AG and Astellas Pharma.